Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat

Neuropharmacology

Volumn 49, Issue 7, 2005, Pages 996-1006

  Bruins Slot, Liesbeth A ^a   Kleven, Mark S ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT1A receptor; Atypical antipsychotics; Phencyclidine; Social interaction deficits

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; 8 BENZOYL N [(7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL)METHYL] 8 AZABICYCLO[3.2.1]OCTANE 3 METHANAMINE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; PHENCYCLIDINE; PIPERAZINE; REMOXIPRIDE; SEROTONIN 1A AGONIST; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSOCIAL WITHDRAWAL; RAT; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIOPATHY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIOXANES; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; INTERPERSONAL RELATIONS; MALE; PHENCYCLIDINE; PIPERAZINES; PYRIDINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; REMOXIPRIDE; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; THIAZOLES; TROPANES;

EID: 27144443377     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.05.013     Document Type: Article

References (65)

1. S. Ahlenius, E. Ericson, V. Hillegaart, L.B. Nilsson, P. Salmi, and A. Wijkstrom In vivo effects of remoxipride and aromatic ring metabolites in the rat Journal of Pharmacology and Experimental Therapeutics 283 1997 1356 1366
2. 2A receptors in pyramidal neurons of prefrontal cortex Cerebral Cortex 14 2004 281 299
3. N.C. Andreasen, M. Flaum, V.W. Swayze, G. Tyrrell, and S. Arndt Positive and negative symptoms in schizophrenia. A critical reappraisal Archives of General Psychiatry 47 1990 615 621
4. L.E. Arvidsson, U. Hacksell, J.L. Nilsson, S. Hjorth, A. Carlsson, P. Lindberg, D. Sanchez, and H. Wikstrom 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist Journal of Medicinal Chemistry 24 1981 921 923
5. C.R. Ashby Jr., and R.Y. Wang Pharmacological actions of the atypical antipsychotic drug clozapine: a review Synapse 24 1996 349 394
6. R.A. Bantick, J.F. Deakin, and P.M. Grasby The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? Journal of Psychopharmacology 15 2001 37 46
7. 1A agonists in the treatment of depression? Biological Psychiatry 53 2003 193 203
8. D. Boulay, R. Depoortere, C. Louis, G. Perrault, G. Griebel, and P. Soubrie SSR181507, a putative atypical antipsychotic with dopamine D(2) antagonist and 5-HT(1A) agonist activities: improvement of social interaction deficits induced by phencyclidine in rats Neuropharmacology 46 2004 1121 1129
9. M.J. Bradbury, D.R. Giracello, D.F. Chapman, G. Holtz, H. Schaffhauser, S.P. Rao, M.A. Varney, and J.J. Anderson Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: interaction with serotonergic systems Neuropharmacology 44 2003 562 572
10. J.S. Brar, K.N. Chengappa, H. Parepally, A.R. Sandman, S.B. Kreinbrook, S.A. Sheth, and R. Ganguli The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms Annals of Clinical Psychiatry 9 1997 227 234
11. 2 receptors Journal of Pharmacology and Experimental Therapeutics 302 2002 381 389
12. Y. Claustre, D.D. Peretti, P. Brun, C. Gueudet, N. Allouard, R. Alonso, J. Lourdelet, A. Oblin, G. Damoiseau, D. Francon, M.F. Suaud-Chagny, R. Steinberg, M. Sevrin, H. Schoemaker, P. George, P. Soubrie, and B. Scatton SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: neurochemical and electrophysiological profile Neuropsychopharmacology 28 2003 2064 2076
13. C. Cosi, and W. Koek Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells European Journal of Pharmacology 433 2001 55 62
14. 1A receptors of novel antipsychotic agents: G-protein activation in native rat brain membranes The International Journal of Neuropsychopharmacology 7 2004 S438 S439
15. 1A receptor agonists: recent developments and controversial issues Psychopharmacology 121 1995 1 26
16. 1A receptor agonist. II: behavioral profile predictive of an atypical antipsychotic activity Neuropsychopharmacology 28 2003 1889 1902
17. J. Elliott, and G.P. Reynolds Agonist-stimulated GTPgamma[35S] binding to 5-HT(1A) receptors in human post-mortem brain European Journal of Pharmacology 386 1999 313 315
18. H. Fink, R. Morgenstern, and W. Oelssner Clozapine - a serotonin antagonist? Pharmacology Biochemistry and Behavior 20 1984 513 517
19. J.H. Gaddum, and K.A. Hameed Drugs which antagonize 5-hydroxytryptamine British Journal of Pharmacology 9 1954 240 248
20. 1A receptor agonist: in vitro and in vivo pharmacology European Neuropsychopharmacology 12 2002 S277
21. M.F. Green, R.S. Kern, D.L. Braff, and J. Mintz Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophrenia Bulletin 26 2000 119 136
22. J. Ichikawa, and H.Y. Meltzer Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs European Archives of Psychiatry and Clinical Neuroscience 249 Suppl. 4 1999 90 98
23. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry 148 1991 1301 1308
24. 1A receptor European Journal of Pharmacology 441 2002 137 140
25. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia American Journal of Psychiatry 157 2000 514 520
26. 2 receptor antagonistic activity Journal of Pharmacology and Experimental Therapeutics 274 1995 329 336
27. 1A activation in attenuation of catalepsy induction in rats. Neuropharmacology, in press. doi:10.1016/j.neuropharm.2005.02.005.
28. J.H. Krystal, D.C. D'Souza, D. Mathalon, E. Perry, A. Belger, and R. Hoffman NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development Psychopharmacology 169 2003 215 233
29. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr., and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Archives of General Psychiatry 51 1994 199 214
30. A.C. Lahti, B. Koffel, D. LaPorte, and C.A. Tamminga Subanesthetic doses of ketamine stimulate psychosis in schizophrenia Neuropsychopharmacology 13 1995 9 19
31. A.C. Lahti, M.A. Weiler, P.K. Corey, R.A. Lahti, A. Carlsson, and C.A. Tamminga Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia Biological Psychiatry 43 1998 2 11
32. J.A. Lowe III, T.F. Seeger, A.A. Nagel, H.R. Howard, P.A. Seymour, J.H. Heym, F.E. Ewing, M.E. Newman, A.W. Schmidt, and J.S. Furman 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents Journal of Medicinal Chemistry 34 1991 1860 1866
33. E.D. Luby, B.D. Cohen, G. Rosenbaum, J.S. Gottlieb, and R. Kelley Study of a new schizophrenomimetic drug: sernyl AMA Archives of Neurology and Psychiatry 81 1959 363 369
34. A.K. Malhotra, D.A. Pinals, C.M. Adler, I. Elman, A. Clifton, D. Pickar, and A. Breier Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics Neuropsychopharmacology 17 1997 141 150
35. A.K. Malhotra, D.A. Pinals, H. Weingartner, K. Sirocco, C.D. Missar, D. Pickar, and A. Breier NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers Neuropsychopharmacology 14 1996 301 307
36. F. Mauler, T. Fahrig, E. Horvath, and R. Jork Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY × 3702 in vitro and in vivo Brain Research 888 2001 150 157
37. A.C. McCreary, J. Glennon, T. Tuinstra, A.H.J. Herremans, J.A.M. Van der Heyden, R. Feenstra, S.K. Long, and C.G. Kruse SLV313: a novel antipsychotic with additional antidepressant and anxiolytic-like actions European Neuropsychopharmacology 12 2002 S274
38. S.R. McGurk The effects of clozapine on cognitive functioning in schizophrenia Journal of Clinical Psychiatry 60 Suppl. 12 1999 24 29
39. 2 affinities differentiate atypical and typical antipsychotic drugs Psychopharmacology Bulletin 25 1989 390 392
40. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Progress in Neuropsychopharmacology and Biological Psychiatry 27 2003 1159 1172
41. M.J. Millan Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors Journal of Pharmacology and Experimental Therapeutics 295 2000 853 861
42. M.J. Millan, R. Schreiber, A. Dekeyne, J.M. Rivet, K. Bervoets, M. Mavridis, C. Sebban, S. Maurel-Remy, A. Newman-Tancredi, M. Spedding, O. Muller, G. Lavielle, and M. Brocco S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol Journal of Pharmacology and Experimental Therapeutics 286 1998 1356 1373
43. A. Newman-Tancredi, S. Gavaudan, C. Conte, C. Chaput, M. Touzard, L. Verriele, V. Audinot, and M.J. Millan Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study European Journal of Pharmacology 355 1998 245 256
44. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia International Journal of Neuropsychopharmacology 11 2005 1 16
45. Y. Oshiro, S. Sato, N. Kurahashi, T. Tanaka, T. Kikuchi, K. Tottori, Y. Uwahodo, and T. Nishi Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl) butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives Journal of Medicinal Chemistry 41 1998 658 667
46. 1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl] piperazines. 1. Synthesis and structure-activity relationships Journal of Medicinal Chemistry 37 1994 99 104
47. E.P. Prinssen, M.S. Kleven, and W. Koek Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin Psychopharmacology 128 1996 191 197
48. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nature Reviews Drug Discovery 3 2004 353 359
49. F. Sams-Dodd Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats Behavioural Pharmacology 6 1995 55 65
50. F. Sams-Dodd Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia Behavioural Pharmacology 7 1996 3 23
51. F. Sams-Dodd Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test Behavioural Pharmacology 8 1997 196 215
52. F. Sams-Dodd Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity Reviews in Neurosciences 10 1999 59 90
53. T.F. Seeger, P.A. Seymour, A.W. Schmidt, S.H. Zorn, D.W. Schulz, L.A. Lebel, S. McLean, V. Guanowsky, H.R. Howard, and J.A. Lowe III Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity Journal of Pharmacology and Experimental Therapeutics 275 1995 101 113
54. J. Semba, A. Watanabe, S. Kito, and M. Toru Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain Neuropharmacology 34 1995 785 791
55. D.A. Shapiro, S. Renock, E. Arrington, L.A. Chiodo, L.X. Liu, D.R. Sibley, B.L. Roth, and R. Mailman Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 2003 1400 1411
56. T. Sumiyoshi, M. Matsui, I. Yamashita, S. Nohara, T. Uehara, M. Kurachi, and H.Y. Meltzer Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia Journal of Clinical Psychopharmacology 20 2000 386 388
57. T. Sumiyoshi, M. Matsui, S. Nohara, I. Yamashita, M. Kurachi, C. Sumiyoshi, K. Jayathilake, and H.Y. Meltzer Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment American Journal of Psychiatry 158 2001 1722 1725
58. T. Sumiyoshi, M. Matsui, I. Yamashita, S. Nohara, M. Kurachi, T. Uehara, S. Sumiyoshi, C. Sumiyoshi, and H.Y. Meltzer The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia Biological Psychiatry 49 2001 861 868
59. C.A. Tamminga Partial dopamine agonists in the treatment of psychosis Journal of Neural Transmission 109 2002 411 420
60. B.J. Van Vliet, J. Mos, J.A.M. Van der Heijden, R. Feenstra, C.G. Kruse, and S.K. Long DU 127090: a highly potent, atypical dopamine receptor ligand - a putative potent full spectrum antipsychotic with low EPS potential European Neuropsychopharmacology 10 Suppl. 3 2000 S293
61. M.L. Wadenberg Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat Neuroscience Biobehavioral Reviews 20 1996 325 339
62. M.L. Wadenberg, and S. Ahlenius Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy Journal of Neural Transmission General Section 83 1991 43 53
63. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats Journal of Pharmacology and Experimental Therapeutics 282 1997 699 706
64. D.W. Woolley, and E. Shaw Some neurophysiological aspects of serotonin British Medical Journal 4880 1954 122 126
65. 2A receptors in neuroendocrine neurons in vivo Journal of Pharmacology and Experimental Therapeutics 310 2004 59 66